Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HIL-216
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : HilleVax
Deal Size : $270.5 million
Deal Type : Licensing Agreement
HilleVax and Kangh Announce Agreement for Hexavalent VLP Norovirus Vaccine Outside China
Details : Under the agreement, HilleVax gain rights to Kangh’s hexavalent virus-like particle (VLP) vaccine candidate for norovirus, referred to by HilleVax as HIL-216, outside of Greater China.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : $15.0 million
January 08, 2024
Lead Product(s) : HIL-216
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : HilleVax
Deal Size : $270.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Recombinant Norovirus Hexavalent Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects
Details : Recombinant Norovirus Hexavalent Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastroenteritis.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : Recombinant Norovirus Hexavalent Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
